PortfoliosLab logo
PortfoliosLab logo
Tools
Portfolios
Screeners
Discussions
ARQT vs. CAMT
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between ARQT and CAMT is 0.29, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

ARQT vs. CAMT

Last updated May 31, 2025

Compare and contrast key facts about Arcutis Biotherapeutics, Inc. (ARQT) and Camtek Ltd (CAMT).

Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: ARQT or CAMT.

Performance

ARQT vs. CAMT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Arcutis Biotherapeutics, Inc. (ARQT) and Camtek Ltd (CAMT). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

ARQT:

0.71

CAMT:

-0.57

Sortino Ratio

ARQT:

1.44

CAMT:

-0.58

Omega Ratio

ARQT:

1.16

CAMT:

0.93

Calmar Ratio

ARQT:

0.58

CAMT:

-0.61

Martin Ratio

ARQT:

3.50

CAMT:

-0.95

Ulcer Index

ARQT:

13.39%

CAMT:

40.48%

Daily Std Dev

ARQT:

72.12%

CAMT:

65.34%

Max Drawdown

ARQT:

-95.02%

CAMT:

-97.74%

Current Drawdown

ARQT:

-64.74%

CAMT:

-51.52%

Fundamentals

Market Cap

ARQT:

$1.63B

CAMT:

$3.15B

EPS

ARQT:

-$1.04

CAMT:

$2.61

PS Ratio

ARQT:

7.66

CAMT:

6.98

PB Ratio

ARQT:

11.42

CAMT:

5.06

Total Revenue (TTM)

ARQT:

$212.82M

CAMT:

$450.86M

Gross Profit (TTM)

ARQT:

$188.12M

CAMT:

$222.30M

EBITDA (TTM)

ARQT:

-$106.93M

CAMT:

$118.40M

Returns By Period

In the year-to-date period, ARQT achieves a -6.39% return, which is significantly higher than CAMT's -17.62% return.

ARQT

YTD

-6.39%

1M

-12.54%

6M

0.00%

1Y

50.58%

3Y*

-14.52%

5Y*

-17.22%

10Y*

N/A

CAMT

YTD

-17.62%

1M

1.84%

6M

-10.68%

1Y

-36.85%

3Y*

31.82%

5Y*

39.31%

10Y*

37.92%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Arcutis Biotherapeutics, Inc.

Camtek Ltd

Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

ARQT vs. CAMT — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
ARQT
The Risk-Adjusted Performance Rank of ARQT is 7575
Overall Rank
The Sharpe Ratio Rank of ARQT is 7474
Sharpe Ratio Rank
The Sortino Ratio Rank of ARQT is 7575
Sortino Ratio Rank
The Omega Ratio Rank of ARQT is 6969
Omega Ratio Rank
The Calmar Ratio Rank of ARQT is 7474
Calmar Ratio Rank
The Martin Ratio Rank of ARQT is 8080
Martin Ratio Rank
CAMT
The Risk-Adjusted Performance Rank of CAMT is 2020
Overall Rank
The Sharpe Ratio Rank of CAMT is 1919
Sharpe Ratio Rank
The Sortino Ratio Rank of CAMT is 2020
Sortino Ratio Rank
The Omega Ratio Rank of CAMT is 2121
Omega Ratio Rank
The Calmar Ratio Rank of CAMT is 1212
Calmar Ratio Rank
The Martin Ratio Rank of CAMT is 2727
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

ARQT vs. CAMT - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Arcutis Biotherapeutics, Inc. (ARQT) and Camtek Ltd (CAMT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current ARQT Sharpe Ratio is 0.71, which is higher than the CAMT Sharpe Ratio of -0.57. The chart below compares the historical Sharpe Ratios of ARQT and CAMT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

ARQT vs. CAMT - Dividend Comparison

Neither ARQT nor CAMT has paid dividends to shareholders.

TTM20242023202220212020201920182017
ARQT
Arcutis Biotherapeutics, Inc.		0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
CAMT
Camtek Ltd		0.00%1.65%0.00%0.00%0.00%0.00%1.57%2.07%2.45%

Drawdowns

ARQT vs. CAMT - Drawdown Comparison

The maximum ARQT drawdown since its inception was -95.02%, roughly equal to the maximum CAMT drawdown of -97.74%. Use the drawdown chart below to compare losses from any high point for ARQT and CAMT.

Loading data...

Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

ARQT vs. CAMT - Volatility Comparison

Arcutis Biotherapeutics, Inc. (ARQT) has a higher volatility of 16.02% compared to Camtek Ltd (CAMT) at 12.27%. This indicates that ARQT's price experiences larger fluctuations and is considered to be riskier than CAMT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Loading data...

Financials

ARQT vs. CAMT - Financials Comparison

This section allows you to compare key financial metrics between Arcutis Biotherapeutics, Inc. and Camtek Ltd. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.

Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities

0.0020.00M40.00M60.00M80.00M100.00M120.00M20212022202320242025
65.85M
118.64M
(ARQT) Total Revenue
(CAMT) Total Revenue
Values in USD except per share items

ARQT vs. CAMT - Profitability Comparison

The chart below illustrates the profitability comparison between Arcutis Biotherapeutics, Inc. and Camtek Ltd over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.
Gross Margin
Operating Margin
Net Margin
Quarterly
Annual
40.0%50.0%60.0%70.0%80.0%90.0%100.0%20212022202320242025
86.6%
51.1%
(ARQT) Gross Margin
(CAMT) Gross Margin
ARQT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Arcutis Biotherapeutics, Inc. reported a gross profit of 57.02M and revenue of 65.85M. Therefore, the gross margin over that period was 86.6%.

CAMT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Camtek Ltd reported a gross profit of 60.56M and revenue of 118.64M. Therefore, the gross margin over that period was 51.1%.

ARQT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Arcutis Biotherapeutics, Inc. reported an operating income of -24.53M and revenue of 65.85M, resulting in an operating margin of -37.3%.

CAMT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Camtek Ltd reported an operating income of 32.70M and revenue of 118.64M, resulting in an operating margin of 27.6%.

ARQT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Arcutis Biotherapeutics, Inc. reported a net income of -25.06M and revenue of 65.85M, resulting in a net margin of -38.1%.

CAMT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Camtek Ltd reported a net income of 34.31M and revenue of 118.64M, resulting in a net margin of 28.9%.